JP2010526101A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010526101A5 JP2010526101A5 JP2010506688A JP2010506688A JP2010526101A5 JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5 JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010506688 A JP2010506688 A JP 2010506688A JP 2010526101 A5 JP2010526101 A5 JP 2010526101A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- compound
- composition
- unit dose
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91564907P | 2007-05-02 | 2007-05-02 | |
| US94792107P | 2007-07-03 | 2007-07-03 | |
| PCT/US2008/062518 WO2008137753A2 (en) | 2007-05-02 | 2008-05-02 | Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526101A JP2010526101A (ja) | 2010-07-29 |
| JP2010526101A5 true JP2010526101A5 (enExample) | 2011-06-23 |
Family
ID=39587015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506688A Withdrawn JP2010526101A (ja) | 2007-05-02 | 2008-05-02 | 直接作用型および可逆的ｐ２ｙ１２阻害剤の静脈および経口投与 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20090048216A1 (enExample) |
| EP (1) | EP2079464A2 (enExample) |
| JP (1) | JP2010526101A (enExample) |
| KR (1) | KR20100029746A (enExample) |
| CN (1) | CN101795682A (enExample) |
| AU (1) | AU2008247483A1 (enExample) |
| BR (1) | BRPI0811476A2 (enExample) |
| CA (1) | CA2686203A1 (enExample) |
| CO (1) | CO6241104A2 (enExample) |
| EA (1) | EA200901473A1 (enExample) |
| EC (1) | ECSP099778A (enExample) |
| GT (1) | GT200900284A (enExample) |
| IL (1) | IL201834A0 (enExample) |
| MA (1) | MA31663B1 (enExample) |
| MX (1) | MX2009011843A (enExample) |
| TN (1) | TN2009000451A1 (enExample) |
| WO (1) | WO2008137753A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2627719C (en) * | 2005-11-03 | 2016-07-12 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
| CN101622234B (zh) * | 2007-03-06 | 2013-08-07 | 诺瓦提斯公司 | 适于治疗炎性或变应性病症的二环有机化合物 |
| US20090156620A1 (en) * | 2007-05-02 | 2009-06-18 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| CA2686221A1 (en) * | 2007-05-02 | 2008-11-13 | Portola Pharmaceuticals, Inc. | [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylurea salts, forms and methods related thereto |
| US9427448B2 (en) * | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| CN102271685A (zh) * | 2008-12-30 | 2011-12-07 | 斯若姆博洛捷克有限公司 | 鉴定发展成器官功能衰竭的风险提高的危重患者的方法及用于其治疗的化合物 |
| US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
| EP2498731B1 (en) | 2009-11-11 | 2020-01-22 | Chiesi Farmaceutici S.p.A. | Methods of treating or preventing stent thrombosis |
| ES2550033T3 (es) * | 2009-12-23 | 2015-11-04 | Ratiopharm Gmbh | Forma de dosificación farmacéutica sólida de ticagrelor |
| WO2011088152A1 (en) | 2010-01-12 | 2011-07-21 | Portola Pharmaceuticals, Inc. | Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof |
| WO2011137459A1 (en) * | 2010-04-30 | 2011-11-03 | Portola Pharmaceuticals, Inc. | Dosage forms of elinogrel and methods of injectable administration thereof |
| US9029095B2 (en) | 2010-12-01 | 2015-05-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method and kits for determining platelet susceptibility to activation in a patient |
| JP2013544271A (ja) * | 2010-12-03 | 2013-12-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 式（ｉ）の化合物の薬学的組成物、投薬形態、および新規の形態、ならびにその使用方法 |
| SG11201908128YA (en) | 2017-03-15 | 2019-10-30 | Idorsia Pharmaceuticals Ltd | Subcutaneous administration of a p2y12 receptor antagonist |
| ES3067885T3 (en) | 2017-06-23 | 2026-05-26 | Chiesi Farm Spa | Cangrelor for the treatment and/or prevention of shunt or stent thrombosis |
| CN107462648B (zh) * | 2017-08-21 | 2019-09-27 | 盐城锦明药业有限公司 | 一种Cangrelor中间体腺苷-2-硫酮的高效液相色谱检测方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6906063B2 (en) | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| CA2627719C (en) | 2005-11-03 | 2016-07-12 | Portola Pharmaceuticals, Inc. | [4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto |
-
2008
- 2008-05-02 US US12/114,630 patent/US20090048216A1/en not_active Abandoned
- 2008-05-02 AU AU2008247483A patent/AU2008247483A1/en not_active Abandoned
- 2008-05-02 CN CN200880023071A patent/CN101795682A/zh active Pending
- 2008-05-02 MX MX2009011843A patent/MX2009011843A/es not_active Application Discontinuation
- 2008-05-02 EA EA200901473A patent/EA200901473A1/ru unknown
- 2008-05-02 KR KR1020097025059A patent/KR20100029746A/ko not_active Withdrawn
- 2008-05-02 EP EP08747561A patent/EP2079464A2/en not_active Withdrawn
- 2008-05-02 JP JP2010506688A patent/JP2010526101A/ja not_active Withdrawn
- 2008-05-02 CA CA002686203A patent/CA2686203A1/en not_active Abandoned
- 2008-05-02 BR BRPI0811476-5A2A patent/BRPI0811476A2/pt not_active IP Right Cessation
- 2008-05-02 WO PCT/US2008/062518 patent/WO2008137753A2/en not_active Ceased
-
2009
- 2009-10-29 IL IL201834A patent/IL201834A0/en unknown
- 2009-10-30 TN TNP2009000451A patent/TN2009000451A1/fr unknown
- 2009-10-30 GT GT200900284A patent/GT200900284A/es unknown
- 2009-11-26 MA MA32377A patent/MA31663B1/fr unknown
- 2009-12-02 EC EC2009009778A patent/ECSP099778A/es unknown
- 2009-12-02 CO CO09137697A patent/CO6241104A2/es not_active Application Discontinuation
-
2011
- 2011-09-16 US US13/235,305 patent/US20120009172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12220392B2 (en) | Combination composition | |
| JP2020033360A5 (enExample) | ||
| JP2008535867A5 (enExample) | ||
| JP2011173928A5 (enExample) | ||
| JP2009102342A5 (enExample) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2014515373A5 (enExample) | ||
| JP2022535894A5 (enExample) | ||
| TWI894333B (zh) | 血管收縮素ii受體拮抗劑代謝產物與ｎｅｐ抑制劑的複合物用於心臟衰竭的應用 | |
| ES2671926T3 (es) | Comprimido recubierto en seco que contiene tegafur, gimeracilo y oteracilo potásico | |
| ES2508490T3 (es) | Formulación de trimetazidina con diferentes perfiles de liberación | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| JP2020510043A5 (enExample) | ||
| CA2964684A1 (en) | Composition for the treatment of conditions involving muscular pain | |
| AU2010277725B2 (en) | Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients | |
| WO2012005605A1 (en) | A combination composition comprising ibuprofen and paracetamol | |
| CN102247330B (zh) | 一种以红花黄色素为原料制备的缓释片剂及其制备方法 | |
| TWI631944B (zh) | 氯硝柳胺及其衍生物的用途 | |
| CN104000814B (zh) | 一种防治痛风性关节炎的药物组合物及其用途 | |
| KR20120089444A (ko) | 정맥내 이부프로펜에 의한 위독한 환자의 치료방법 | |
| ES2782898T3 (es) | Métodos de administración de compuestos agonistas de la trombopoyetina | |
| JP2009538822A (ja) | 静脈におけるウイルスの治療 | |
| ES2952013T3 (es) | Combinación de ibuprofeno y tramadol para aliviar el dolor | |
| JP2022540854A5 (enExample) | ||
| JP2008527034A5 (enExample) |